Abstract

Trabecular meshwork constitutes the conventional outflow pathway and controls intraocular pressure by regulating aqueous outflow. Mechanical stimulation has been studied as one of the triggers to regulate aqueous outflow in trabecular meshwork, but it is not well understood. We investigated that how transient receptor potential cation channel subfamily V member 4 (TRPV4) functions in human trabecular meshwork cells (HTMC) and affects intraocular pressure (IOP). HTMC were treated with TRPV4 siRNA, followed by incubation for 24 hours. We confirmed the suppression of TRPV4 mRNA expression and the reduction of Ca2+ influx by the TRPV4 agonist GSK1016790A in TRPV4 siRNA-treated HTMC. TRPV4 siRNA-treated HTMC exhibited a significant reduction in Ca2+ influx and production of arachidonic acid and prostaglandin (PG) E2 induced by mechanical stretch, and direct activation of TRPV4 by GSK1016790A increased production of arachidonic acid, PGE2, and PGD2 and inhibited gel contraction. Furthermore, TRPV4-deficient mice had higher IOP than wild-type mice, and GSK1016790A administration lowered IOP. These results suggest that TRPV4 mediates the cellular response induced by trabecular meshwork stretch, leading to IOP reduction through the production of prostaglandins and inhibition of cell contraction. Targeting TRPV4 may have therapeutic benefits that lead to lowering IOP in glaucoma patients.

Highlights

  • Glaucoma is a disease that cause visual defect due to injury of optic nerve and is a leading cause of blindness in modern society [1]

  • In human trabecular meshwork cells (HTMC) incubated with the Ca2+ indicator Fluo-8, TRPV4 siRNA treatment significantly suppressed the increase in intracellular Ca2+ by GSK1016790A (Control siRNA, 4.67±0.24 arbitrary units (A.U.), siRNA#1, 3.16 ± 0.19 A.U., and siRNA#2, 3.40 ± 0.17 A.U., Fig 1B–1D)

  • These results collectively indicate that TRPV4 plays an important role in cellular response to mechanical stretch, regulating trabecular meshwork (TM)

Read more

Summary

Introduction

Glaucoma is a disease that cause visual defect due to injury of optic nerve and is a leading cause of blindness in modern society [1]. Evidence-based treatment for glaucoma, including normal tension glaucoma, is defined as lowering intraocular pressure (IOP) [2, 3]. IOP-lowering drugs mainly have a mechanism that suppress the production of aqueous humor from ciliary body or reduces aqueous humor drainage resistance via the uveoscleral route. The major route for aqueous humor drainage is the conventional outflow. TRPV4 mediates mechanosensory transduction in TM and regulates IOP. Pharmaceutical Co.,Ltd. The other authors declare no competing interests. The other authors declare no competing interests This does not alter our adherence to PLOS ONE policies on sharing data and materials

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call